SLC37A4 sirna

SLC37A4 siRNA (Human)

Cat. Num. AAA8206095

• Gene Names: SLC37A4; G6PT1; G6PT2; G6PT3; GSD1b; GSD1c; GSD1d; TRG19; TRG-19; PRO0685
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SLC37A4; SLC37A4 siRNA (Human); G6PT; G6PT1; Glucose-6-phosphate translocase; Glucose-5-phosphate transporter; Solute carrier family 37 member 4; Transformation-related gene 19 protein; TRG-19; SLC37A4 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: SLC37A4 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 451

• Applicable Applications for SLC37A4 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SLC37A4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SLC37A4 sirna

siRNA to inhibit SLC37A4 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 256219483
• NCBI GeneID: 2542
• NCBI Accession #: NP_001157749.1
• NCBI GenBank Nucleotide #: NM_001164277.1
• UniProt Accession #: O43826; O96016; Q5J7V4; Q9UI19; Q9UNS4
• Molecular Weight: 48,840 Da
• NCBI Official Full Name: glucose-6-phosphate translocase isoform 1
• NCBI Official Synonym Full Names: solute carrier family 37 (glucose-6-phosphate transporter), member 4
• NCBI Official Symbol: SLC37A4
• NCBI Official Synonym Symbols: G6PT1; G6PT2; G6PT3; GSD1b; GSD1c; GSD1d; TRG19; TRG-19; PRO0685
• NCBI Protein Information: glucose-6-phosphate translocase
• UniProt Protein Name: Glucose-6-phosphate translocase
• Protein Family: Glucose-6-phosphate exchanger
• UniProt Gene Name: SLC37A4
• UniProt Synonym Gene Names: G6PT; G6PT1; TRG-19
• UniProt Entry Name: G6PT1_HUMAN

NCBI Description

This gene regulates glucose-6-phosphate transport from the cytoplasm to the lumen of the endoplasmic reticulum, in order to maintain glucose homeostasis. It also plays a role in ATP-mediated calcium sequestration in the lumen of the endoplasmic reticulum. Mutations in this gene have been associated with various forms of glycogen storage disease. Alternative splicing in this gene results in multiple transcript variants.[provided by RefSeq, Aug 2009]

Uniprot Description

SLC37A4: Transports glucose-6-phosphate from the cytoplasm to the lumen of the endoplasmic reticulum. Forms with glucose-6- phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels. Defects in SLC37A4 are the cause of glycogen storage disease type 1B (GSD1B). GSD1B is a metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. GSD1 patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia. GSD1B patients also present a tendency towards infections associated with neutropenia, relapsing aphthous gingivostomatitis, and inflammatory bowel disease. Defects in SLC37A4 are the cause of glycogen storage disease type 1C (GSD1C). Defects in SLC37A4 are the cause of glycogen storage disease type 1D (GSD1D). Belongs to the major facilitator superfamily. Organophosphate:Pi antiporter (OPA) (TC 2.A.1.4) family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Transporter; Transporter, SLC family; Membrane protein, multi-pass; Membrane protein, integral

Chromosomal Location of Human Ortholog: 11q23.3

Cellular Component: endoplasmic reticulum membrane; membrane; endoplasmic reticulum; integral to membrane; integral to endoplasmic reticulum membrane

Molecular Function: transporter activity; glucose-6-phosphate transmembrane transporter activity

Biological Process: transport; glucose-6-phosphate transport; hexose transport; carbohydrate metabolic process; glucose metabolic process; pathogenesis; glucose transport; glucose homeostasis; transmembrane transport

Disease: Glycogen Storage Disease Ic; Glycogen Storage Disease Ib